France· FR:64224915
NABUCOM 500 mg, comprimé pelliculé
A nabumetone product containing nabumétone, registered in France by ARROW GENERIQUES, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Nabumetone is registered in 14 of 19 countries.
Countries holding a registration under ATC M01AX01 (nabumetone), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 8 of them publish a price we can compare per daily dose
Nabumetone · ATC M01AX01
14 / 19 countries
- Belgiumprice
- Canada
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of nabumetone costs, country by country.
Normalised to the WHO defined daily dose (1 g), the median price runs from $0.37 in France to $0.73 in Italy — a ×2.0 gap.
- France: $0.37 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Nabumetone · price per daily dose (1 g)
USD · FX 28 Sept 2026
- IT Italy$0.73
- FR France$0.37
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- NABUMÉTONE
- Manufacturer
- ARROW GENERIQUES
- Country
- France (FR)
- ATC code
- M01AX01
- ATC class
- Nabumetone
- Defined daily dose
- 1 g, O
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip133400933271152plaquette(s) thermoformée(s) PVC PVDC aluminium de 28 comprimé(s)EUR 4.61
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
289 interactions on record for nabumetone.
Graded by severity as the source publishes them — 57 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Nabumetone · interactions on record
289 records
- 57 severe
- 142 moderate
- 4 minor
- 86 info
Most severe, free to view
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
- DalteparinB01AB04severe
- EnoxaparinB01AB05severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Nabumetone in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesNabumetoneAmerican Health Packaging
- FinlandNabumeton Bmm PharmaBMM Pharma AB
- IrelandNabumetone Tillomed 500 mg Film-coated TabletsTillomed Pharma GmbH
- BelgiumGambaran 500 mgViatris Healthcare
- SwedenRelifex 500 mg Filmdragerad tablettViatris AB
- NorwayRelifexViatris AS
- IcelandRelifexViatris ApS
- NetherlandsMebutan 500 mg, tablettenViatris Healthcare B.V.
Authorised across Europe · EMA
The same active substance is authorised in 17 EEA countries. Names it is sold under:
- Belgium · Gambaran, Nabumeton Tillomed
- Germany · Relifex
- Estonia · Relifex
- Spain · Relif
- United Kingdom (Northern Ireland) · Nabumetone Accord-Uk, Nabumetone Kent Pharma Uk
- Greece · Akratol, Nabuton
- Hungary · Relifex
- Ireland · Nabumetone Tillomed, Relifex
- Iceland · Relifex
- Italy · Nabuser
- Lithuania · Relifex
- Luxembourg · Gambaran
- Latvia · Relifex
- Netherlands · Mebutan, Mebutan Dispers
- Norway · Relifex
- Poland · Nabuton Vp
- Sweden · Relifex
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/07e12d0d-6da3-4b93-9c57-f208a62e8d69 GET /v1/drugs/07e12d0d-6da3-4b93-9c57-f208a62e8d69?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "64224915",
"date_amm": "1990-04-30",
"type_amm": "Procédure nationale",
"numero_ue": null,
"substance": "NABUMÉTONE",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé pelliculé",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about nabumetone.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.